These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34253592)

  • 1. Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses.
    Stratenwerth B; Geisen SM; He Y; Beltzig L; Sturla SJ; Kaina B
    Mol Cancer Ther; 2021 Oct; 20(10):1789-1799. PubMed ID: 34253592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
    Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
    Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
    Reich TR; Schwarzenbach C; Vilar JB; Unger S; Mühlhäusler F; Nikolova T; Poplawski A; Baymaz HI; Beli P; Christmann M; Tomicic MT
    Cell Mol Life Sci; 2021 Jul; 78(14):5587-5604. PubMed ID: 34100981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.
    Knizhnik AV; Roos WP; Nikolova T; Quiros S; Tomaszowski KH; Christmann M; Kaina B
    PLoS One; 2013; 8(1):e55665. PubMed ID: 23383259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.
    Zhang WB; Wang Z; Shu F; Jin YH; Liu HY; Wang QJ; Yang Y
    J Biol Chem; 2010 Dec; 285(52):40461-71. PubMed ID: 20880848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological and mass spectrometry-based approaches to determine thresholds of the mutagenic DNA adduct O
    Kraus A; McKeague M; Seiwert N; Nagel G; Geisen SM; Ziegler N; Trantakis IA; Kaina B; Thomas AD; Sturla SJ; Fahrer J
    Arch Toxicol; 2019 Feb; 93(2):559-572. PubMed ID: 30446773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells.
    Beltzig L; Stratenwerth B; Kaina B
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
    Naumann SC; Roos WP; Jöst E; Belohlavek C; Lennerz V; Schmidt CW; Christmann M; Kaina B
    Br J Cancer; 2009 Jan; 100(2):322-33. PubMed ID: 19127257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
    Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
    Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide.
    Sato Y; Kurose A; Ogawa A; Ogasawara K; Traganos F; Darzynkiewicz Z; Sawai T
    Cancer Biol Ther; 2009 Mar; 8(5):452-7. PubMed ID: 19305157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accidental Encounter of Repair Intermediates in Alkylated DNA May Lead to Double-Strand Breaks in Resting Cells.
    Fujii S; Fuchs RP
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs.
    Roos WP; Nikolova T; Quiros S; Naumann SC; Kiedron O; Zdzienicka MZ; Kaina B
    DNA Repair (Amst); 2009 Jan; 8(1):72-86. PubMed ID: 18840549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells.
    Kaina B; Beltzig L; Piee-Staffa A; Haas B
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
    Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB.
    Aasland D; Götzinger L; Hauck L; Berte N; Meyer J; Effenberger M; Schneider S; Reuber EE; Roos WP; Tomicic MT; Kaina B; Christmann M
    Cancer Res; 2019 Jan; 79(1):99-113. PubMed ID: 30361254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
    Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
    Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
    [No Abstract]   [Full Text] [Related]  

  • 18. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
    Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
    Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status.
    Kinashi Y; Ikawa T; Takahashi S
    Appl Radiat Isot; 2020 Sep; 163():109204. PubMed ID: 32561044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
    Eich M; Roos WP; Nikolova T; Kaina B
    Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.